Summary: Opioids are commonly prescribed to help people with chronic non‑malignant pain sleep better, but a systematic review from the University of Warwick and Lausanne University Hospital finds the evidence for sleep benefits is limited, inconsistent and of poor quality. Opioid use may also increase the risk of sleep-disordered breathing such as sleep apnea.
Source: University of Warwick
Background and purpose
Chronic pain frequently disrupts sleep, creating a cycle in which poor sleep worsens pain and greater pain further impairs sleep. To break that cycle, many patients are prescribed opioid medications with the expectation that reduced pain will lead to improved sleep. An interdisciplinary research team from the University of Warwick, in collaboration with Lausanne University Hospital, reviewed the existing evidence to determine whether opioid therapy reliably improves sleep quality in people with chronic non‑malignant pain.
Methods
The researchers carried out a systematic review and exploratory meta-analysis of studies published up to July 2017 that assessed the effects of opioids on sleep. They identified 18 eligible studies involving 3,746 patients, including twelve randomized controlled trials lasting up to 12 months. The most commonly evaluated opioids were morphine sulfate, oxycodone and transdermal fentanyl. Only a small number of trials used objective sleep measurements (for example, polysomnography) alongside patient self-reports and sleep diaries.
Main findings
Overall, the review found only limited and low‑quality evidence that opioids improve sleep in people with chronic pain. While some patients reported modest subjective improvements in sleep, objective sleep metrics such as total sleep time and proportion of deep sleep did not consistently show benefit. In some studies, opioid therapy was associated with fewer movements in bed and fewer awakenings, but these apparent gains sometimes coincided with increased sleep‑disordered breathing and shortened REM sleep latency.
The pooled effect on self‑reported sleep quality was small (standardised mean difference of approximately 0.36) and inconsistent across studies. Many trials had methodological weaknesses, including unclear or high risk of bias, potential publication bias, conflicts of interest, and a general lack of screening for sleep apnea before and during treatment. Where daytime functioning was assessed, reports of sedation and excessive daytime sleepiness were common.
Risks: breathing and sleep‑disordered breathing
Opioids act on brainstem mechanisms that regulate breathing and can increase the likelihood of pauses or partial obstructions in breathing during sleep. Symptoms of sleep‑disordered breathing can include loud snoring, gasping for air, dry mouth and morning headaches. The review also notes that insomnia is more common among people with chronic pain who are prescribed opioids compared with those who are not, underscoring the complex relationship between pain, opioid therapy and sleep.
Short‑term versus long‑term effects
Some evidence suggested that low to moderate opioid doses might lead to small short‑term improvements in subjective sleep for a subset of patients, but this benefit was not robust across objective measures and was not clearly sustained over time. Higher opioid doses did not consistently produce better sleep outcomes and were often linked to greater adverse effects, including daytime drowsiness.
Expert comments
Lead author Dr Nicole Tang (Department of Psychology) highlights a key discrepancy between subjective and physiological assessments of sleep: “Patients often report improved sleep even when objective measures show no increase in restorative sleep stages. This mismatch may reflect the difficulty of interpreting varied bodily sensations after starting opioid therapy.”
Dr Harbinder Sandhu (Warwick Medical School), who is also working on a large clinical trial to help people reduce opioid use and manage chronic pain with non‑pharmacological approaches, adds: “Short‑term pain relief from opioids is well documented, but long‑term benefits for pain and sleep remain unclear. Better evidence will inform safer prescribing and patient counselling. Anyone concerned about opioid therapy should discuss it with their GP.”
Dr Chantal Berna, a pain physician at Lausanne University Hospital, recommends careful assessment when considering or continuing long‑term opioid treatment: “Decisions should balance potential risks and benefits. Measuring vigilance and sleep both subjectively and with overnight objective tests before and after initiating opioids can be useful, because some side effects and risks may not be obvious to patients.”
Conclusions and recommendations
The systematic review concludes that current evidence does not convincingly support opioid therapy as a reliable way to improve sleep for patients with chronic non‑malignant pain. Where sleep did appear to improve subjectively, objective measures often failed to corroborate those reports, and increased risk of sleep‑disordered breathing and daytime sedation were concerns. The authors call for higher‑quality trials with rigorous methodology, transparent reporting, routine screening for sleep apnea, and combined use of objective and subjective sleep assessments to clarify both benefits and harms.
Source:
University of Warwick
Media contact:
Alice Scott – University of Warwick
Image source:
The image is in the public domain.
Original research:
“The effect of opioid therapy on sleep quality in patients with chronic non‑malignant pain: A systematic review and exploratory meta‑analysis.” Nicole K. Y. Tang, Maria T. Stella, Ptolemy D. W. Banks, Harbinder K. Sandhu, Chantal Berna. Published in Sleep Medicine Reviews. The review synthesised data from multiple trials and concluded that opioid therapy may produce small, inconsistent self‑reported sleep benefits but carries risks that require further high‑quality research.